Chapter: 18 — Antiparkinson's Disease Drugs — Module: Park-Module 3 — Dyskinesias, Motor Complications, and Advanced Levodopa Management Tier: T1
1. A 64-year-old man with an 11-year history of Parkinson's disease reports involuntary writhing movements of his trunk and arms that begin approximately 40 minutes after each levodopa dose and resolve over the following hour as the medication wears off. He notes that his gait and dexterity are actually best during these episodes. Which of the following most precisely characterizes the phenomenology and timing of this movement disorder?
A) Sustained painful dystonic contractions of the distal lower extremities occurring at the lowest point of the levodopa plasma concentration curve, reflecting insufficient dopaminergic stimulation in the off state
B) Stereotyped rhythmic leg movements appearing twice per dose cycle — at the onset and offset of levodopa effect — with relative freedom from involuntary movements at peak concentration
C) Choreiform involuntary movements emerging at or near peak plasma levodopa concentration during the functionally on state, when postsynaptic dopamine receptor stimulation is most intense in the context of sensitized striatal neurons
D) Ballistic flinging movements of the proximal upper extremities appearing exclusively during transitions between on and off states, caused by abrupt changes in subthalamic nucleus firing rate
E) Irregular myoclonic jerks occurring throughout the dose cycle without correlation to plasma levodopa concentration, reflecting generalized cortical hyperexcitability from chronic dopaminergic stimulation
ANSWER: C
Rationale:
Option C is correct. This patient has peak-dose dyskinesia (PDD), the most common form of levodopa-induced dyskinesia (LID), accounting for approximately 75–80% of cases. The defining phenomenological and temporal features are: choreiform or athetoid involuntary movements; emergence at or near peak plasma levodopa concentrations, typically 30–60 minutes after an oral dose; and occurrence during the functionally on state when the patient has the best motor function. The clinical observation that his gait and dexterity are best during these episodes is a hallmark of PDD — patients are motorically functional, even improved, but with superimposed involuntary movements. This distinguishes PDD from conditions where abnormal movements coincide with motor deterioration. The underlying mechanism is years of pulsatile, non-physiological D1 receptor stimulation in the setting of progressive nigrostriatal degeneration, which sensitizes direct pathway medium spiny neurons through deltaFosB accumulation and downstream AMPA/NMDA receptor upregulation.
Option A: Option A is incorrect; it describes off-period dystonia — sustained painful contractions at the levodopa nadir, reflecting insufficient dopamine, the opposite temporal and pathophysiological pattern from PDD.
Option B: Option B is incorrect; it describes diphasic dyskinesia, which occurs at rising and falling intermediate concentrations with relative freedom at the peak — the inverse timing from PDD.
Option D: Option D is incorrect; ballistic proximal upper extremity movements during on-off transitions is not a recognized phenomenological description of any established levodopa-related movement disorder category, and abrupt STN firing rate change as the described mechanism conflates DBS physiology with dyskinesia pathophysiology.
Option E: Option E is incorrect; myoclonic jerks without correlation to the plasma concentration curve do not characterize LID, which is specifically tied to the dose cycle timing.
2. A 71-year-old woman with advanced Parkinson's disease describes involuntary leg movements that occur in two distinct waves with each levodopa dose — first as the medication begins working and again as it wears off — with a relatively dyskinesia-free window during the period of best motor function. Her previous neurologist had reduced her levodopa dose to treat these movements, which worsened them. Which of the following best explains why dose reduction worsens this specific pattern of dyskinesia?
A) Diphasic dyskinesia occurs at intermediate plasma levodopa concentrations during the rising and falling phases of each dose cycle; reducing the individual dose prolongs the time the plasma concentration spends traversing these intermediate levels on both the ascending and descending limbs, increasing the duration of the dyskinesia trigger window without reaching the peak concentration where the patient is relatively free of involuntary movements
B) Diphasic dyskinesia is caused by excessive peak dopamine receptor stimulation, and dose reduction attenuates this peak insufficiently in patients with advanced disease because compensatory upregulation of D1 receptors amplifies the response to any remaining levodopa-derived dopamine
C) Dose reduction worsens diphasic dyskinesia by increasing the proportion of levodopa converted to 3-O-methyldopa via peripheral COMT activity, which crosses the blood-brain barrier and competitively inhibits dopamine binding at postsynaptic receptors during the off-to-on transition
D) Diphasic dyskinesia results from dopaminergic denervation hypersensitivity in the indirect pathway, and dose reduction increases indirect pathway activity, which paradoxically amplifies involuntary movement through disinhibition of the subthalamic nucleus
E) Reducing levodopa dose accelerates gastric emptying, causing more rapid and erratic levodopa absorption that increases the rate of change of plasma concentration and thereby amplifies the concentration-transition dyskinesias
ANSWER: A
Rationale:
Option A is correct. Diphasic dyskinesia — also called D-I-D (dyskinesia-improvement-dyskinesia) — is defined by its occurrence at intermediate plasma levodopa concentrations during both the ascending phase (beginning-of-dose, BOD dyskinesia) and the descending phase (end-of-dose, EOD dyskinesia), with relative freedom from involuntary movements at peak concentration when the patient is in the best motor state. Reducing the individual levodopa dose lowers the peak concentration achieved, which means the plasma concentration curve must traverse the intermediate dyskinesia-triggering range for a longer time on the way up before either reaching a sufficient peak or failing to reach it altogether. It also extends the time spent at intermediate concentrations on the descent. The net result is more time spent in the dyskinesia-triggering window and less time — if any — at the peak where the patient is dyskinesia-free. This is the pharmacokinetic basis for why dose reduction is contraindicated in diphasic dyskinesia and why the management goal is the opposite: to reduce inter-dose concentration fluctuations, ideally by achieving continuous delivery.
Option B: Option B is incorrect; diphasic dyskinesia is not caused by excessive peak stimulation — that is the mechanism of peak-dose dyskinesia. Attributing it to D1 receptor upregulation amplifying residual dopamine misidentifies the concentration-timing mechanism entirely.
Option C: Option C is incorrect; 3-O-methyldopa does not cross the blood-brain barrier effectively and does not act as a competitive inhibitor at postsynaptic dopamine receptors — this is a fabricated mechanism with no pharmacological basis in the management of diphasic dyskinesia.
Option D: Option D is incorrect; diphasic dyskinesia sensitization is centered on the direct pathway D1-expressing medium spiny neurons, not indirect pathway mechanisms, and dose reduction does not produce disinhibition of the STN in the manner described.
Option E: Option E is incorrect; levodopa dose reduction does not accelerate gastric emptying, and the rate of change of plasma concentration is not the established trigger for diphasic dyskinesia — it is the absolute concentration level relative to an intermediate threshold.
3. A 68-year-old man with a 13-year history of Parkinson's disease reports waking at approximately 4:30 AM with severe cramping and inversion of his right foot, which resolves within 30 minutes after he takes his first levodopa dose of the day. He takes his last dose at 10 PM and his first morning dose at 6 AM. Neurological examination during daytime on-state is notable only for mild resting tremor. Which of the following is the most pharmacologically precise explanation for his early morning episodes?
A) Peak-dose dyskinesia from residual levodopa accumulation overnight, in which the long half-life of his evening dose produces supraphysiological striatal dopamine concentrations during the early morning hours that manifest as focal lower extremity dystonia
B) Diphasic dyskinesia triggered by the transition from the overnight off state to the onset of the first morning dose, in which rising plasma levodopa concentrations pass through the intermediate dyskinesia-triggering threshold before reaching peak
C) Nocturnal myoclonus caused by dopaminergic denervation of spinal cord interneurons, producing rhythmic lower extremity contractions independent of the plasma levodopa concentration curve
D) Drug-induced akathisia from chronic levodopa exposure producing an irresistible urge to move the lower extremities, misinterpreted as dystonia because of the patient's underlying extrapyramidal disease
E) Off-period dystonia reflecting severely reduced dopaminergic stimulation during the prolonged overnight levodopa trough, in which insufficient D1 and D2 receptor occupancy in the basal ganglia motor circuit produces sustained involuntary contraction and equinovarus posturing of the foot and calf
ANSWER: E
Rationale:
Option E is correct. This patient has classic off-period dystonia, the third principal pattern of levodopa-associated movement disorder. The critical pharmacokinetic observation is that his episodes occur at 4:30 AM — six and a half hours after his last evening dose and ninety minutes before his first morning dose. Given levodopa's typical oral half-life of approximately 90 minutes and standard overnight fasting conditions, plasma levodopa at 4:30 AM is negligible, placing the patient at the nadir of dopaminergic stimulation. Off-period dystonia results from this state of insufficient D1 and D2 receptor occupancy in the basal ganglia: the reduced dopaminergic tone increases the inhibitory output of the internal globus pallidus and substantia nigra pars reticulata to the thalamus, and the resulting motor circuit imbalance produces sustained, often painful involuntary muscle contractions. The foot and calf are the most frequently affected sites, characteristically adopting an equinovarus posture. Resolution with the first morning levodopa dose — as described — is diagnostically confirmatory. Management targets extending dopaminergic coverage through the overnight period, typically with controlled-release carbidopa/levodopa at bedtime.
Option A: Option A is incorrect; levodopa does not accumulate overnight to produce supraphysiological concentrations — its short plasma half-life of approximately 90 minutes means it is essentially cleared within 4–5 hours of the last dose, the opposite of accumulation.
Option B: Option B is incorrect; diphasic dyskinesia requires an active dose cycle with rising concentrations passing through an intermediate threshold; at 4:30 AM with no recent dose, there is no ascending concentration curve, making this mechanism inapplicable.
Option C: Option C is incorrect; nocturnal myoclonus is a distinct condition involving rhythmic jerks at sleep onset, not sustained painful contractions resolving with dopaminergic medication; dopaminergic denervation of spinal cord interneurons is not the established mechanism of off-period dystonia.
Option D: Option D is incorrect; akathisia produces a subjective urge to move with restlessness, not sustained painful involuntary foot posturing with an equinovarus deformity, and the resolution with levodopa rather than with movement is inconsistent with akathisia.
4. A 56-year-old woman with young-onset Parkinson's disease develops peak-dose dyskinesias after only 2 years of levodopa therapy at a modest dose of carbidopa/levodopa 25/100 mg three times daily. A 78-year-old man with late-onset Parkinson's disease has taken carbidopa/levodopa 25/250 mg four times daily for 8 years without dyskinesias. Which of the following best explains why the younger patient developed dyskinesias earlier despite a lower cumulative levodopa dose?
A) Young-onset Parkinson's disease is associated with a genetic variant that upregulates striatal D1 receptor expression at baseline, making these receptors constitutively supersensitive to any level of dopaminergic stimulation independent of cumulative levodopa exposure
B) Greater nigrostriatal degeneration relative to age in young-onset disease eliminates the presynaptic terminal buffering capacity that normally moderates synaptic dopamine fluctuations; each levodopa dose therefore produces more extreme receptor occupancy swings from saturation to near-zero, driving sensitization more rapidly regardless of absolute dose
C) Young-onset patients have higher gastrointestinal motility, producing faster and more complete levodopa absorption and consequently higher peak plasma concentrations per dose that overwhelm receptor desensitization mechanisms more rapidly than lower peak concentrations in older patients
D) The blood-brain barrier is more permeable in younger patients, allowing a higher fraction of each oral levodopa dose to enter the CNS and produce greater striatal dopamine concentration peaks that initiate sensitization after fewer exposures
E) Young-onset Parkinson's disease involves earlier and more complete loss of inhibitory cholinergic interneurons in the striatum, which normally suppress direct pathway medium spiny neuron activity; their loss disinhibits direct pathway firing and produces dyskinesia sensitization independent of the dopaminergic input pattern
ANSWER: B
Rationale:
Option B is correct. The key pharmacological principle is that dyskinesia risk is driven primarily by the amplitude of receptor occupancy swings per dose, not by cumulative dose, and this amplitude is determined by the degree of nigrostriatal degeneration rather than by the dose itself. In the intact nigrostriatal system, the dense terminal field of dopaminergic neurons acts as a pharmacokinetic buffer: vesicular storage absorbs peaks in levodopa-derived dopamine during absorption and releases stored dopamine during troughs, damping the oscillation in synaptic concentration. As terminals are lost with disease progression, this buffering capacity falls proportionally. Young-onset Parkinson's disease is associated with a more aggressive nigrostriatal degeneration course relative to the patient's age — by the time levodopa is required, greater terminal loss has occurred relative to reserve. Each oral dose therefore produces more extreme swings in striatal dopamine concentration: more rapid saturation during absorption, more complete depletion during the trough. These extreme oscillations drive pulsatile D1 receptor activation, DARPP-32/deltaFosB accumulation, and direct pathway sensitization more rapidly than the same dose would in a patient with less terminal depletion. The older patient with preserved terminal density — even at higher doses — experiences more damped oscillations and slower sensitization.
Option A: Option A is incorrect; constitutive D1 receptor supersensitivity from a genetic variant causing baseline upregulation is not an established mechanism distinguishing young-onset from late-onset PD dyskinesia risk — the relevant variable is acquired terminal loss, not genetically determined receptor density.
Option C: Option C is incorrect; gastrointestinal motility differences between young and older patients are not the established explanation for differential LID risk, and faster absorption affecting peak plasma concentration is a peripheral pharmacokinetic argument that does not account for the central buffering mechanism that is the actual determinant.
Option D: Option D is incorrect; blood-brain barrier permeability differences between age groups are not an established explanation for differential LID risk, and levodopa crosses the BBB via the large neutral amino acid transporter rather than by passive diffusion through a permeable barrier.
Option E: Option E is incorrect; cholinergic interneuron loss is not the mechanism differentiating young-onset from late-onset dyskinesia risk — the established presynaptic buffering mechanism involves dopaminergic terminals, not cholinergic interneurons.
5. Repeated pulsatile D1 receptor stimulation in the striatum initiates a molecular sensitization cascade in direct pathway medium spiny neurons that underlies the development of levodopa-induced dyskinesia. Which of the following correctly traces the sequence from receptor activation to the transcriptional change most consistently associated with dyskinesia severity?
E) D1 receptor activation → Gs coupling → adenylyl cyclase → cyclic AMP → PKA → direct phosphorylation of deltaFosB at Ser-27 → deltaFosB stabilization against proteasomal degradation → transcriptional activation of glutamate receptor genes
ANSWER: D
Rationale:
Option D is correct. The cascade begins with D1 receptor activation of Gs-coupled adenylyl cyclase, elevating cyclic AMP and activating protein kinase A (PKA). PKA phosphorylates DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein of 32 kDa) at threonine-34, converting it into a potent inhibitor of protein phosphatase 1 (PP1). This PP1 inhibition amplifies and sustains PKA-dependent signaling by preventing dephosphorylation of PKA substrates. The resulting sustained downstream signaling drives progressive expression of FosB gene products; because full-length FosB is rapidly degraded while the truncated isoform deltaFosB is resistant to proteasomal degradation, deltaFosB accumulates with each exposure. DeltaFosB then drives transcriptional upregulation of AMPA receptor GluA1 subunits and NMDA receptor NR2B subunits in direct pathway medium spiny neurons, increasing their sensitivity to both dopaminergic and glutamatergic inputs. This molecular sensitization — deltaFosB accumulation and downstream receptor subunit changes — is the most consistently demonstrated correlate of dyskinesia severity across rodent and primate models.
Option A: Option A is incorrect; D1 receptors are Gs-coupled, not Gq-coupled. Gq coupling activating phospholipase C-beta, IP3, and PKC is the signaling pathway of D2-like receptors acting through Gq in some systems, and more specifically of muscarinic M1 and alpha-1 adrenergic receptors — not D1.
Option B: Option B is incorrect; while beta-arrestin-mediated ERK signaling has been studied in the context of biased agonism at GPCRs, the canonical cascade linking pulsatile D1 stimulation to LID sensitization in the established pharmacological literature runs through Gs/cAMP/PKA/DARPP-32, not through beta-arrestin/ERK.
Option C: Option C is incorrect; PKA does not directly phosphorylate NMDA receptor NR2B subunits as the primary downstream step in this cascade — DARPP-32 is the canonical PKA substrate that amplifies the signal, and NR2B upregulation is a transcriptional consequence of deltaFosB accumulation, not a direct PKA phosphorylation event.
Option E: Option E is incorrect; PKA does not directly phosphorylate deltaFosB at Ser-27 to stabilize it — deltaFosB's accumulation results from its intrinsic resistance to proteasomal degradation as a truncated isoform, not from PKA-mediated phosphorylation stabilization. This option correctly identifies the Gs/cAMP/PKA pathway initiation but fabricates the mechanism of deltaFosB accumulation.
6. Amantadine reduces levodopa-induced dyskinesias through antagonism of NMDA-subtype ionotropic glutamate receptors. Which of the following most precisely describes the pharmacological mechanism of this antagonism and explains why it selectively attenuates dyskinesia rather than impairing all NMDA receptor-mediated synaptic transmission?
A) Amantadine binds to the glycine co-agonist site on the NMDA receptor and reduces the probability of channel opening in response to glutamate, providing tonic reduction of NMDA receptor activity that is greatest when baseline glutamatergic tone is lowest and receptor occupancy is highest
B) Amantadine is a competitive antagonist at the glutamate binding site of the NMDA receptor NR2 subunit, displacing endogenous glutamate most effectively when synaptic glutamate concentrations are elevated during dyskinesia expression and least effectively during normal corticostriatal transmission
C) Amantadine is an uncompetitive open-channel blocker of the NMDA receptor — it enters the ion channel pore only when the channel is open following glutamate and glycine binding, blocking it in a use-dependent fashion; this selectivity for actively gated channels means its blocking effect is proportionally greater during periods of excessive corticostriatal glutamatergic drive than during normal synaptic activity
D) Amantadine binds to the NR2B subunit at an allosteric site distinct from both the glutamate and glycine binding sites, producing a conformational change that reduces single-channel conductance without altering the frequency of channel opening, thereby attenuating the magnitude of each synaptic NMDA current
E) Amantadine blocks NMDA receptors at extrasynaptic locations specifically, where tonic glutamate activates NR2B-containing receptors that drive the transcriptional sensitization underlying dyskinesia, while sparing synaptic NR2A-containing receptors that mediate normal corticostriatal long-term potentiation
ANSWER: C
Rationale:
Option C is correct. Amantadine is an uncompetitive NMDA receptor antagonist, meaning it does not compete with glutamate or glycine at their respective binding sites but instead enters the ion channel pore only after the channel has been opened by the binding of both glutamate and its glycine co-agonist. This open-channel block mechanism is use-dependent: the drug can only access its binding site within the channel when the channel is in the open state, so its blocking efficacy is directly proportional to the frequency of channel opening. Under normal corticostriatal synaptic transmission, NMDA channels open at baseline rates and amantadine's effect is modest. In the sensitized striatum during dyskinesia expression, the excessive corticostriatal glutamatergic drive opens NMDA channels at substantially higher frequency, and amantadine's open-channel blocking effect is proportionally greater. This use-dependence is the pharmacological basis for the selective attenuation of pathological glutamatergic excess while largely preserving normal synaptic transmission — and consequently for the ability to reduce dyskinesia without substantially impairing the dopaminergic motor benefit of levodopa.
Option A: Option A is incorrect; amantadine does not bind to the glycine co-agonist site. Glycine site antagonists (such as 7-chlorokynurenic acid) are a distinct class; amantadine acts within the open channel pore. The description of its effect being greatest when receptor occupancy is highest inverts the pharmacological logic of open-channel block.
Option B: Option B is incorrect; amantadine is not a competitive antagonist at the glutamate binding site on the NR2 subunit. Competitive antagonism at the NR2 glutamate site is the mechanism of AP5 and similar research compounds; amantadine's channel-blocking mechanism is explicitly uncompetitive.
Option D: Option D is incorrect; amantadine does not bind to an NR2B allosteric site reducing single-channel conductance — that description more closely resembles the mechanism of ifenprodil-type NR2B-selective negative allosteric modulators, not amantadine.
Option E: Option E is incorrect; the distinction between synaptic NR2A-containing and extrasynaptic NR2B-containing NMDA receptors as the basis for amantadine's selectivity is a theoretical framework sometimes applied to memantine but is not the established explanation for amantadine's antidyskinetic selectivity as described in the clinical pharmacology literature.
7. A 77-year-old man with Parkinson's disease and levodopa-induced dyskinesias has a serum creatinine of 2.2 mg/dL and an estimated creatinine clearance of 32 mL/min. He is started on amantadine for dyskinesia management. Which of the following statements about amantadine's pharmacokinetics most directly determines the dose adjustment required in this patient?
A) Amantadine is excreted largely unchanged in the urine with minimal hepatic metabolism, giving renal function exclusive control over its elimination; its plasma half-life of 10–18 hours in normal renal function is prolonged in proportion to the degree of renal impairment, requiring reduction to 100 mg once daily for creatinine clearance of 30–50 mL/min to prevent accumulation and neuropsychiatric toxicity
B) Amantadine undergoes significant first-pass hepatic metabolism by CYP2D6, and reduced renal blood flow in chronic kidney disease secondarily impairs hepatic CYP2D6 activity, requiring dose reduction to prevent accumulation of the parent compound
C) Amantadine is 90% protein-bound in plasma; renal impairment reduces serum albumin, increasing the free drug fraction and lowering the apparent volume of distribution, requiring a reduced loading dose but not a reduced maintenance dose in patients with creatinine clearance below 50 mL/min
D) Amantadine undergoes renal tubular secretion as its sole elimination pathway; glomerular filtration does not contribute, so dose adjustment should be based on tubular secretion markers such as fractional excretion of uric acid rather than creatinine clearance
E) Amantadine's active metabolite, N-acetyl-amantadine, accumulates in renal impairment and is responsible for both the antidyskinetic effect and the neuropsychiatric toxicity; dose reduction targets the metabolite rather than the parent compound
ANSWER: A
Rationale:
Option A is correct. Amantadine's pharmacokinetic profile makes renal function the sole determinant of its elimination and therefore of its required dose adjustment. It has an oral bioavailability of approximately 86–90%, is not substantially metabolized by the liver, and is excreted largely unchanged in the urine through a combination of glomerular filtration and tubular secretion. Its plasma half-life in patients with normal renal function is approximately 10–18 hours. Because hepatic metabolism contributes negligibly to clearance, any reduction in renal function directly and proportionally prolongs the half-life, increasing steady-state plasma concentrations and the risk of concentration-dependent adverse effects — particularly neuropsychiatric toxicity including confusion, hallucinations, and agitation. The established dose adjustment thresholds are: creatinine clearance 30–50 mL/min → 100 mg once daily; CrCl 15–29 mL/min → 100 mg every other day or avoidance. This patient's CrCl of 32 mL/min falls in the range requiring reduction to 100 mg once daily.
Option B: Option B is incorrect; amantadine does not undergo significant CYP2D6-mediated first-pass hepatic metabolism. Hepatic clearance is minimal, and the mechanism described — renal impairment reducing hepatic CYP activity — is not an established pharmacokinetic interaction for amantadine.
Option C: Option C is incorrect; amantadine is not highly protein-bound. High protein binding with reduced albumin increasing the free fraction is a relevant consideration for drugs like phenytoin, valproate, and warfarin — not for amantadine. The statement about reducing the loading dose but not the maintenance dose further contradicts the actual clinical requirement, which is a reduction in maintenance dosing.
Option D: Option D is incorrect; while renal tubular secretion does contribute to amantadine's renal elimination, glomerular filtration also participates, and dose adjustment is based on creatinine clearance as a measure of overall renal function — not on tubular secretion markers such as fractional excretion of uric acid.
Option E: Option E is incorrect; amantadine does not have a clinically significant active metabolite called N-acetyl-amantadine that accumulates in renal impairment. Amantadine is excreted primarily as unchanged parent drug; dose adjustment targets the accumulation of the parent compound itself.
8. A movement disorder specialist is selecting pharmacological treatment for a patient with Parkinson's disease whose peak-dose dyskinesias have become functionally limiting. Which of the following most accurately represents the evidence base for amantadine as first-line treatment for levodopa-induced dyskinesia?
A) Amantadine carries a Level B evidence recommendation for LID reduction, based on a single pivotal phase 3 trial demonstrating 30% dyskinesia reduction; its designation as first-line therapy reflects the absence of competing agents rather than robust efficacy data
B) Amantadine has demonstrated antidyskinetic efficacy of approximately 20–30% in controlled trials, but is designated first-line because it is the only oral agent that simultaneously reduces dyskinesia and extends on-time, a combination not achieved by any other oral pharmacological intervention
C) Amantadine is supported by Level A evidence but only for patients within the first 5 years of levodopa therapy, after which sensitization is too established for NMDA antagonism to meaningfully reduce glutamatergic permissive drive
D) Amantadine's antidyskinetic efficacy is highly variable — effective in approximately 30% of patients and ineffective in 70% — reflecting pharmacogenomic variation in NMDA receptor NR2B subunit expression that has not yet been characterized sufficiently to allow patient selection
E) Multiple controlled trials and a Cochrane systematic review support a Level A evidence designation for immediate-release amantadine in LID reduction, with dyskinesia improvement of approximately 45–60% without a commensurate worsening of motor function — a dissociation that distinguishes it from strategies that reduce dyskinesia by attenuating dopaminergic stimulation
ANSWER: E
Rationale:
Option E is correct. Amantadine is the only oral agent with robust Level A evidence for reducing established levodopa-induced dyskinesias. The evidence base encompasses multiple randomized controlled trials and a Cochrane systematic review, consistently demonstrating that immediate-release amantadine at standard doses (100 mg two to three times daily) reduces peak-dose dyskinesia by approximately 45–60%. The clinically defining feature of this benefit — which validates amantadine's position as first-line therapy — is that this dyskinesia reduction occurs without a commensurate worsening of motor function in most patients. This dissociation is pharmacologically coherent: because amantadine's mechanism targets the glutamatergic permissive drive rather than dopaminergic stimulation itself, it can attenuate dyskinesia expression without reducing the dopaminergic signal responsible for on-state motor benefit. This is the key distinction from strategies such as levodopa dose reduction, which inevitably worsen motor control when used to manage dyskinesia. The antidyskinetic effect is maintained in most patients for at least one year, though some attenuation with longer-term use has been reported.
Option A: Option A is incorrect; amantadine carries Level A evidence, not Level B, and is supported by multiple controlled trials rather than a single pivotal trial. A 30% reduction figure understates the evidence.
Option B: Option B is incorrect; the reduction in controlled trials is approximately 45–60%, not 20–30%, and while Gocovri ER does reduce off-time in addition to dyskinesia, the claim that no other oral agent achieves combined dyskinesia reduction and on-time extension overstates the distinction from other agents.
Option C: Option C is incorrect; amantadine's Level A designation is not restricted to the first 5 years of levodopa therapy — it is used precisely in patients with established, long-standing dyskinesias, and its mechanism targets the glutamatergic permissive drive that enables dyskinesia expression regardless of sensitization duration.
Option D: Option D is incorrect; amantadine's response rate is not characterized by pharmacogenomic variation in NR2B expression, and describing a 30% responder rate contradicts the controlled trial literature showing approximately 45–60% dyskinesia reduction across patient populations.
9. A 69-year-old woman with Parkinson's disease has been taking amantadine 100 mg three times daily for 6 months with good dyskinesia control. She presents with a net-like, reddish-purple discoloration of the skin over both lower legs that has developed gradually over the past 2 months. She has no leg pain, swelling, or warmth, and no systemic symptoms. Peripheral pulses are intact. Which of the following is the correct characterization and management of this finding?
A) Chronic venous insufficiency exacerbated by amantadine-mediated peripheral vasoconstriction, requiring compression stockings, leg elevation, and dose reduction to prevent progression to venous ulceration
B) Livedo reticularis, a common cutaneous adverse effect of amantadine occurring in up to 50% of patients on long-term therapy, caused by altered vasomotor tone in the superficial dermal plexus rather than by vasculitis or thrombosis; it is benign, does not require drug discontinuation, and is managed by patient reassurance and monitoring
C) Early peripheral arterial disease accelerated by amantadine-mediated alpha-adrenergic vasoconstriction, requiring vascular surgery evaluation and discontinuation of amantadine to prevent critical limb ischemia
D) Amantadine-induced small-vessel vasculitis from immune complex deposition requiring immediate discontinuation of amantadine, rheumatological evaluation, and consideration of systemic corticosteroids to prevent organ involvement
E) Cutaneous manifestation of dopaminergic dysregulation causing aberrant autonomic control of dermal vasomotor tone, which will resolve when levodopa dose is optimized and amantadine can be tapered; the finding is an indication to reassess the need for continued amantadine rather than to continue it unchanged
ANSWER: B
Rationale:
Option B is correct. Livedo reticularis is a well-established and distinctive cutaneous adverse effect of amantadine, recognized in up to 50% of patients on long-term therapy. It presents as a mottled, net-like or lace-like reddish-purple discoloration of the skin, most commonly on the lower extremities, caused by altered vasomotor tone in the superficial dermal venous plexus — specifically, focal venous pooling and relative stasis in the cutaneous circulation producing the characteristic reticular pattern. The mechanism is vasomotor dysregulation, not inflammation, thrombosis, or arterial insufficiency. Despite its striking appearance, livedo reticularis from amantadine is entirely benign: it does not progress to ulceration, necrosis, or systemic involvement, and it does not require drug discontinuation. The appropriate management is patient education and reassurance. In a patient with well-controlled dyskinesias on amantadine, as in this case, the clinical benefit of continuing therapy substantially outweighs the cosmetic concern of livedo reticularis.
Option A: Option A is incorrect; livedo reticularis from amantadine is a vasomotor phenomenon in the superficial dermal plexus and is distinct from chronic venous insufficiency, which involves incompetent venous valves, dependent edema, skin hyperpigmentation, and ultimately stasis dermatitis — none of which are present here. Compression stockings are not the management.
Option C: Option C is incorrect; livedo reticularis is not a manifestation of peripheral arterial disease or alpha-adrenergic vasoconstriction causing arterial insufficiency. Peripheral arterial disease presents with claudication, reduced ankle-brachial index, and absent or diminished pulses — not a net-like venous discoloration.
Option D: Option D is incorrect; vasculitis would be expected to produce palpable purpura, tenderness, constitutional symptoms, or evidence of organ involvement, and would require inflammatory workup. The presentation described — bilateral, painless, net-like discoloration without systemic features after 6 months of amantadine — is classic livedo reticularis with no vasculitic features.
Option E: Option E is incorrect; livedo reticularis is specifically an adverse effect of amantadine itself and is not caused by dopaminergic dysregulation requiring levodopa optimization — it is not an indication to taper amantadine in a patient who is benefiting from it.
10. A 73-year-old man with Parkinson's disease taking carbidopa/levodopa 25/100 mg four times daily and amantadine 200 mg twice daily is admitted for elective hip arthroplasty. The anesthesia team discontinues all home medications on the morning of surgery. On postoperative day 3 he develops fever to 39.8°C, severe generalized rigidity, diaphoresis, tachycardia, and obtundation. CK is markedly elevated. Which of the following best identifies the pharmacological basis of this complication and its precipitating mechanism?
A) Serotonin syndrome precipitated by the combination of carbidopa/levodopa — which increases central serotonin availability through levodopa's conversion by aromatic amino acid decarboxylase in serotonergic neurons — and the opioid analgesics typically administered perioperatively, which inhibit serotonin reuptake
B) Malignant hyperthermia triggered by inhalational anesthetic agents in a patient with subclinical ryanodine receptor dysfunction, exacerbated by amantadine's NMDA-blocking effects, which impair calcium buffering in skeletal muscle during halothane or sevoflurane exposure
C) Neuroleptic malignant syndrome (NMS) caused by the inadvertent administration of a dopamine antagonist antiemetic — such as metoclopramide or haloperidol — by the surgical team during the perioperative period, producing acute central dopamine receptor blockade in a patient whose baseline dopaminergic tone is already compromised by Parkinson's disease
D) An NMS-like syndrome precipitated by abrupt withdrawal of both carbidopa/levodopa and amantadine, producing a sudden reduction in central dopaminergic tone; amantadine's dopaminergic contributions — dopamine release enhancement and reuptake inhibition — are lost simultaneously with levodopa, producing a more severe and rapid-onset dopaminergic withdrawal state than levodopa discontinuation alone would generate
E) Anticholinergic toxidrome from systemic absorption of atropine used in anesthetic premedication, compounded by amantadine's muscarinic M1 blocking properties that shift the cholinergic-dopaminergic balance in the basal ganglia toward cholinergic excess, producing hyperthermia and altered consciousness
ANSWER: D
Rationale:
Option D is correct. This presentation — fever, severe rigidity, autonomic instability, and markedly elevated CK — is an NMS-like syndrome precipitated by abrupt withdrawal of dopaminergic medications. The critical prescribing error was stopping all home medications on the morning of surgery. Amantadine's pharmacological relevance to the severity of this syndrome extends beyond its NMDA antagonism: it also enhances dopamine synthesis and release from presynaptic terminals and inhibits dopamine reuptake via the dopamine transporter. These dopaminergic mechanisms contribute meaningfully to maintaining central dopaminergic tone, particularly in a patient with advanced Parkinson's disease and depleted nigrostriatal reserve. When both carbidopa/levodopa and amantadine are simultaneously discontinued, the combined loss of exogenous levodopa substrate and the dopamine-enhancing effects of amantadine produces a more abrupt and severe reduction in striatal dopamine availability than either agent's discontinuation alone. The resulting sudden drop in central dopaminergic tone generates the NMS-like state, which is pharmacologically identical to classic NMS except that it results from dopamine deficiency from withdrawal rather than from dopamine receptor blockade by an antipsychotic. The module explicitly identifies abrupt amantadine discontinuation — especially at high doses — as a recognized clinical hazard requiring tapering.
Option A: Option A is incorrect; serotonin syndrome characteristically presents with clonus, hyperreflexia, and agitation — not the severe lead-pipe rigidity and CK elevation of NMS. Carbidopa/levodopa does not substantially increase central serotonin; levodopa is converted to dopamine, not serotonin, by AADC.
Option B: Option B is incorrect; malignant hyperthermia is triggered by inhalational agents in genetically susceptible individuals with RYR1 mutations and presents intraoperatively with rapidly rising temperature and metabolic acidosis — not on postoperative day 3 following routine anesthesia. Amantadine's NMDA blockade does not affect skeletal muscle ryanodine receptors.
Option C: Option C is incorrect; while administration of a dopamine antagonist antiemetic could produce NMS in a PD patient, the stem does not identify such an agent being given, and the primary precipitating factor explicitly described is the discontinuation of all home medications — making dopaminergic withdrawal the identified mechanism, not inadvertent dopamine antagonism.
Option E: Option E is incorrect; atropine does not produce an anticholinergic toxidrome at perioperative doses sufficient to cause fever, rigidity, and CK elevation; amantadine's anticholinergic properties are modest and would not produce this syndrome; and the described mechanism — cholinergic-dopaminergic imbalance shifting toward cholinergic excess — would produce tremor and bradykinesia, not NMS-like hyperthermia and rigidity.
11. A patient with Parkinson's disease and functionally limiting peak-dose dyskinesias has had only partial response to immediate-release amantadine 100 mg three times daily. His neurologist proposes switching to amantadine extended-release (Gocovri 274 mg). Which of the following correctly describes the pharmacokinetic rationale for the extended-release formulation and the clinical benefit demonstrated in pivotal trials that is not consistently seen with immediate-release amantadine?
A) Gocovri is taken in the morning and achieves peak plasma concentrations during the afternoon when peak-dose dyskinesias are typically most severe, providing targeted antidyskinetic coverage during the highest-risk period while producing low concentrations during sleep that minimize overnight neuropsychiatric adverse effects
B) Gocovri uses an enteric-coated delayed-release mechanism that bypasses gastric absorption, delivering the entire 274 mg dose directly to the small intestinal mucosa for more complete and consistent absorption than immediate-release capsules that are subject to gastric acid degradation
C) Gocovri is taken at bedtime and produces a pharmacokinetic profile with low plasma concentrations during sleep — minimizing overnight neuropsychiatric adverse effects — and rising concentrations through the early morning and waking hours; at the higher exposures achieved with this formulation, pivotal trials demonstrated reduction in both peak-dose dyskinesia and off-time, with the off-time benefit not consistently observed with standard immediate-release amantadine
D) Gocovri is an osmotic controlled-release formulation producing a flat 24-hour plasma concentration profile that eliminates the peak-to-trough fluctuations of immediate-release dosing, providing steady-state amantadine exposure equivalent to continuous intravenous infusion throughout the day and night
E) Gocovri achieves its additional clinical benefit over immediate-release amantadine through a dual mechanism — NMDA receptor antagonism at standard amantadine concentrations combined with sigma-1 receptor agonism at the higher concentrations achieved only with the extended-release formulation — producing complementary antidyskinetic and neuroprotective effects not possible at IR doses
ANSWER: C
Rationale:
Option C is correct. Gocovri (amantadine extended-release, 274 mg) is taken at bedtime and uses a specific sustained-release technology designed to produce low plasma amantadine concentrations during the overnight sleep period — when the neuropsychiatric adverse effects of amantadine (insomnia, confusion, hallucinations) are most disruptive — and a rising concentration profile through the early morning and daytime waking hours, when levodopa-related motor activity and dyskinesias are most clinically relevant. This pharmacokinetic engineering allows higher total amantadine exposures to be tolerated than are achievable with immediate-release formulations dosed during waking hours, because the periods of highest plasma concentration coincide with waking rather than sleep. The pivotal phase 3 trials (EASE LID study and confirmatory trial) demonstrated that Gocovri reduced both peak-dose dyskinesia and off-time — the reduction in off-time is an important clinical distinction from immediate-release amantadine, where off-time reduction has not been consistently demonstrated, possibly because the higher amantadine exposures achievable with Gocovri provide additional dopaminergic motor benefit beyond NMDA antagonism alone.
Option A: Option A is incorrect; Gocovri is taken at bedtime, not in the morning — this option reverses the dosing time and therefore misrepresents the pharmacokinetic profile entirely. High concentrations during waking hours are achieved by the rising curve resulting from bedtime dosing, not from morning dosing producing afternoon peaks.
Option B: Option B is incorrect; Gocovri is not an enteric-coated formulation bypassing gastric absorption, and immediate-release amantadine capsules are not subject to significant gastric acid degradation. The release mechanism of Gocovri is a sustained-release capsule technology producing delayed and prolonged absorption, not enteric coating preventing gastric dissolution.
Option D: Option D is incorrect; Gocovri does not produce a flat 24-hour concentration profile equivalent to continuous intravenous infusion. Its pharmacokinetic rationale is specifically a time-shaped profile — low at night, high during the day — not a flat continuous-release profile.
Option E: Option E is incorrect; sigma-1 receptor agonism at higher amantadine concentrations is not an established mechanism contributing to Gocovri's clinical benefit over immediate-release amantadine. The additional benefit is attributed to the higher overall amantadine exposure achievable with the ER formulation and its timing relative to waking hours, not to a distinct receptor mechanism activated only at high concentrations.
12. A 67-year-old man with advanced Parkinson's disease continues to have 4–5 hours of daily off-time and functionally limiting dyskinesias despite optimized oral therapy including carbidopa/levodopa, entacapone, and amantadine. His neurologist proposes levodopa-carbidopa intestinal gel (LCIG) infusion. Which of the following correctly identifies the pharmacokinetic mechanism by which LCIG reduces motor complications and the magnitude of benefit demonstrated in its pivotal trial?
A) LCIG delivers a continuous suspension of levodopa and carbidopa directly into the proximal jejunum via a PEG-J tube, bypassing the gastric emptying variability that causes erratic oral levodopa absorption in Parkinson's disease patients with impaired gastrointestinal motility; the pivotal double-blind, double-dummy randomized controlled trial demonstrated approximately 4 hours of mean daily off-time reduction compared with optimized oral immediate-release carbidopa/levodopa over 12 weeks, with parallel dyskinesia reduction
B) LCIG delivers levodopa intravenously through a subcutaneous port connected to a central venous catheter, achieving 100% bioavailability and bypassing the entire gastrointestinal tract; compared with oral therapy, the pivotal trial showed a mean 6-hour reduction in off-time at the cost of a 40% increase in dyskinesia severity requiring dose downward titration
C) LCIG is a subcutaneous depot formulation of levodopa that is absorbed through the abdominal subcutaneous tissue at a controlled rate determined by the depot polymer matrix, producing plasma levodopa concentrations equivalent to intravenous infusion with the convenience of once-daily administration
D) LCIG delivers carbidopa/levodopa directly into the stomach through a standard percutaneous endoscopic gastrostomy tube in a continuous liquid suspension, reducing the variability of tablet disintegration and dissolution but still subject to the gastric emptying delays that contribute to motor fluctuations in advanced Parkinson's disease
E) LCIG bypasses both gastrointestinal absorption and peripheral decarboxylation by delivering L-DOPA directly into the portal circulation as a prodrug that is converted to dopamine by hepatic aromatic amino acid decarboxylase before entering the systemic circulation and crossing the blood-brain barrier
ANSWER: A
Rationale:
Option A is correct. Levodopa-carbidopa intestinal gel (LCIG, marketed as Duopa in North America and Duodopa in Europe) is a continuous suspension of levodopa 20 mg/mL and carbidopa 5 mg/mL delivered directly into the proximal jejunum via a percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J). The pharmacokinetic rationale is specifically the elimination of gastric emptying as a variable in levodopa absorption. In Parkinson's disease, gastric motility is impaired by the autonomic dysfunction that accompanies the disease, producing erratic and unpredictable gastric emptying that is the primary source of the variable oral levodopa absorption responsible for motor fluctuations. By delivering the drug distal to the stomach — directly to the proximal jejunum, where levodopa absorption via the large neutral amino acid transporter is most efficient — LCIG provides a continuous and predictable levodopa input that closely approximates the continuous dopaminergic stimulation hypothesis target. The pivotal phase 3 double-blind, double-dummy randomized controlled trial demonstrated a mean reduction of approximately 4 hours in daily off-time compared with optimized oral immediate-release carbidopa/levodopa over 12 weeks, with parallel reductions in dyskinesia severity.
Option B: Option B is incorrect; LCIG is not an intravenous preparation delivered through a central venous catheter. It is a gastrointestinal delivery system. The 6-hour off-time reduction figure and the 40% dyskinesia increase are fabricated and do not correspond to the pivotal trial findings.
Option C: Option C is incorrect; LCIG is not a subcutaneous depot formulation. It is a jejunal infusion via a surgically placed PEG-J tube requiring an external infusion pump. Subcutaneous apomorphine infusion is a separate continuous delivery approach using a different drug.
Option D: Option D is incorrect; LCIG delivers directly into the proximal jejunum, not into the stomach. A standard PEG tube with intragastric delivery would still be subject to gastric emptying variability — the jejunal extension tube is precisely what distinguishes LCIG from gastric delivery.
Option E: Option E is incorrect; LCIG does not deliver a prodrug into the portal circulation for hepatic conversion. Levodopa administered by LCIG is the same active amino acid as in oral tablets; it still requires peripheral decarboxylation inhibition by carbidopa and crosses the blood-brain barrier as intact levodopa for CNS conversion to dopamine.
13. A 72-year-old woman has been on levodopa-carbidopa intestinal gel (LCIG) infusion for 22 months with excellent motor control. She now presents with a 4-month history of progressive distal sensory loss and weakness in her feet and hands. Nerve conduction studies show reduced amplitudes of sensory nerve action potentials with relatively preserved conduction velocities, consistent with an axonal sensorimotor polyneuropathy. Laboratory evaluation reveals a plasma homocysteine of 38 µmol/L (normal <15) and a low-normal vitamin B12. Which of the following best identifies the pathophysiological mechanism linking LCIG therapy to this complication?
A) Chronic jejunal infusion causes local mucosal inflammation at the infusion site that impairs absorption of fat-soluble vitamins, including vitamin D, whose deficiency produces a demyelinating peripheral neuropathy through impaired Schwann cell myelin synthesis
B) High-dose levodopa delivered continuously by LCIG is directly neurotoxic to peripheral sensory neurons through oxidative stress from dopamine auto-oxidation metabolites that accumulate in dorsal root ganglion cells when central dopamine synthesis exceeds local antioxidant capacity
C) The carbidopa in LCIG inhibits peripheral aromatic amino acid decarboxylase, preventing the synthesis of pyridoxal phosphate from dietary pyridoxine in peripheral tissues; accumulated pyridoxine substrate is then shunted through an alternative pathway that produces a neurotoxic pyridoxine metabolite responsible for the axonal neuropathy
D) Continuous LCIG infusion produces chronic hyperdopaminergia in the enteric nervous system, causing retrograde axonal degeneration beginning in the myenteric plexus that spreads centripetally through the peripheral nervous system to produce a length-dependent sensorimotor neuropathy
E) Carbidopa, delivered in high daily doses via LCIG, forms a hydrazone complex with pyridoxal phosphate — the active form of vitamin B6 — depleting the cofactor required for transsulfuration pathway enzymes including cystathionine beta-synthase; impaired homocysteine remethylation elevates plasma homocysteine, and the combined B6 depletion and hyperhomocysteinemia produce an axonal sensorimotor polyneuropathy
ANSWER: E
Rationale:
Option E is correct. Peripheral neuropathy associated with long-term LCIG therapy has been recognized as a distinct clinical entity linked to the high daily carbidopa doses that continuous jejunal infusion delivers — substantially higher than those achievable with oral dosing regimens. Carbidopa is a hydrazine derivative that forms a stable hydrazone complex with pyridoxal phosphate (PLP), the active cofactor form of vitamin B6. This complexation depletes the available PLP pool in peripheral tissues. PLP is an essential cofactor for numerous enzymatic reactions, including the transsulfuration pathway enzymes — cystathionine beta-synthase and cystathionine gamma-lyase — that metabolize homocysteine. Depletion of PLP impairs homocysteine metabolism, leading to hyperhomocysteinemia, as seen in this patient (homocysteine 38 µmol/L). The combination of B6 deficiency and hyperhomocysteinemia is directly neurotoxic to peripheral axons, producing the axonal sensorimotor polyneuropathy confirmed by nerve conduction studies showing reduced amplitudes with preserved velocities (axonal pattern, not demyelinating). Vitamin B12 co-deficiency, also present in this patient, amplifies hyperhomocysteinemia by impairing the methylcobalamin-dependent homocysteine remethylation pathway. The module identifies this neuropathy as a distinct recognized clinical entity associated with LCIG.
Option A: Option A is incorrect; the neuropathy is axonal, not demyelinating, and fat-soluble vitamin D deficiency producing Schwann cell demyelination is not the established mechanism — the LCIG neuropathy is specifically linked to B6/B12 deficiency and hyperhomocysteinemia, not vitamin D.
Option B: Option B is incorrect; direct neurotoxicity of levodopa-derived dopamine auto-oxidation metabolites accumulating in dorsal root ganglion cells is not an established mechanism for LCIG-associated neuropathy. The neuropathy is nutritional/metabolic, not oxidative.
Option C: Option C is incorrect; carbidopa does not prevent the synthesis of pyridoxal phosphate from pyridoxine — it forms a complex with pyridoxal phosphate that is already formed, depleting the active cofactor form. The shunting of pyridoxine substrate into a neurotoxic metabolite is a fabricated mechanism.
Option D: Option D is incorrect; enteric nervous system hyperdopaminergia causing retrograde axonal degeneration spreading centripetally is not an established mechanism. The enteric nervous system involvement in PD is a disease-related phenomenon, and LCIG does not cause retrograde centripetal degeneration from the myenteric plexus.
14. A movement disorder center is evaluating four patients with Parkinson's disease for deep brain stimulation (DBS). Patient profiles are as follows: Patient 1 — age 62, 9-year disease duration, UPDRS Part III improves 48% with levodopa challenge, refractory wearing-off and dyskinesias; Patient 2 — age 67, 7-year disease duration, UPDRS Part III improves 18% with levodopa challenge, prominent freezing of gait and postural instability; Patient 3 — age 58, 6-year disease duration, UPDRS Part III improves 35% with levodopa challenge, MoCA 17/30 indicating significant cognitive impairment; Patient 4 — age 71, 11-year disease duration, UPDRS Part III improves 41% with levodopa challenge, mild depression well-controlled on sertraline. Which patient is the strongest DBS candidate based on established selection criteria?
A) Patient 3, because the younger age and adequate levodopa responsiveness establish the strongest pharmacological rationale for DBS, and cognitive impairment is a relative rather than absolute contraindication that can be managed with careful programming of stimulation parameters
B) Patient 1, who meets all core DBS selection criteria: confirmed levodopa responsiveness exceeding the 30–33% UPDRS Part III threshold, refractory motor complications (wearing-off and dyskinesias) that are the primary indication, disease duration establishing long-term levodopa exposure, and the absence of the major contraindications present in the other candidates
C) Patient 4, because age over 70 confers no additional surgical risk in contemporary DBS series, mild depression on a stable antidepressant is not a contraindication, and the levodopa response of 41% is the highest among the candidates whose motor complications are refractory
D) Patient 2, because freezing of gait and postural instability are the motor complications most reliably improved by subthalamic nucleus DBS in contemporary series, and the moderate levodopa response of 18% reflects residual nigrostriatal function that predicts a clinically meaningful DBS response
E) Patient 4 and Patient 1 are equally strong candidates because both have adequate levodopa responsiveness and refractory motor complications; the decision between them should be based solely on which patient is willing to undergo bilateral versus unilateral implantation
ANSWER: B
Rationale:
Option B is correct. Patient 1 meets all established core criteria for DBS candidacy: levodopa responsiveness of 48%, which substantially exceeds the minimum threshold of 30–33% improvement in UPDRS Part III during a standardized levodopa challenge; refractory motor complications — wearing-off and dyskinesias — that are the primary clinical indications for DBS; 9 years of disease duration establishing confirmed Parkinson's disease diagnosis and adequate levodopa exposure history; and the absence of the specific contraindications that disqualify the other candidates. The fundamental pharmacological rationale for DBS — that it modulates the basal ganglia output nuclei to improve the same levodopa-responsive symptoms through a parallel circuit mechanism — requires that symptoms be levodopa-responsive to predict DBS benefit.
Option A: Option A is incorrect; significant cognitive impairment (MoCA 17/30) is one of the strongest contraindications to DBS, not a manageable relative contraindication. DBS does not benefit and may worsen cognition, and patients with dementia are at substantially higher risk of neuropsychiatric deterioration post-implantation. The levodopa responsiveness and age of Patient 3 do not override this contraindication.
Option C: Option C is incorrect; while age 71 and mild controlled depression are not absolute contraindications, Patient 4 is not the strongest candidate when compared with Patient 1, who has comparable motor indications, a similar levodopa response, and no neuropsychiatric vulnerability. The framing in this option overstates the insignificance of age and depression in the comparative assessment.
Option D: Option D is incorrect; freezing of gait and postural instability are specifically identified as levodopa-unresponsive symptoms that DBS does not improve — they are not the primary target of STN stimulation and are explicitly listed as non-responsive features. Furthermore, Patient 2's levodopa response of only 18% falls below the minimum 30–33% threshold, which is the most fundamental disqualifying criterion.
Option E: Option E is incorrect; the decision between Patient 1 and Patient 4 is not equally weighted nor is it based solely on unilateral versus bilateral implantation preference — Patient 1 has a superior overall profile with no neuropsychiatric vulnerabilities, while the comparison of the two candidates involves more than implantation laterality.
15. A 63-year-old man with Parkinson's disease has been approved for DBS. He has severe functionally limiting peak-dose dyskinesias, mild pre-existing anxiety treated with escitalopram, and mildly reduced scores on formal neuropsychological testing. His motor complications are refractory to optimized oral therapy including amantadine. His neurologist is choosing between subthalamic nucleus (STN) and globus pallidus interna (GPi) as the stimulation target. Which of the following best characterizes the pharmacologically relevant trade-offs between the two targets for this specific patient?
A) STN DBS is preferred because it produces greater improvement in UPDRS Part III total motor scores than GPi DBS across all patient subgroups in the VA/NINDS cooperative study, and this superior overall motor benefit outweighs the modestly increased neuropsychiatric risk in patients with mild pre-existing anxiety and cognitive vulnerability
B) GPi DBS is preferred because it increases levodopa dose requirements after implantation — unlike STN DBS, which allows dose reduction — and this patient's severe dyskinesias require maintaining high levodopa doses that the indirect antidyskinetic effect of STN stimulation would necessitate reducing
C) STN DBS is preferred because STN stimulation directly suppresses the overactive direct pathway medium spiny neurons responsible for dyskinesia expression in the sensitized striatum, producing a more powerful antidyskinetic effect than GPi stimulation that acts only through reduction of GPi inhibitory output to the thalamus
D) GPi DBS is preferred for this patient because it carries a lower risk of mood and cognitive adverse effects than STN DBS — an important advantage given his mild pre-existing anxiety and cognitive vulnerability — and provides direct antidyskinetic benefit independent of levodopa dose reduction, allowing doses to be maintained or increased while still controlling his severe dyskinesias; STN DBS's antidyskinetic mechanism relies primarily on the secondary levodopa dose reduction it permits, which would risk worsening motor control
E) The two targets are interchangeable for this patient because the VA/NINDS cooperative study found identical outcomes on all motor, cognitive, and psychiatric measures at every time point, and the choice should be based entirely on surgical team experience with each target rather than on patient-specific clinical factors
ANSWER: D
Rationale:
Option D is correct. This patient's profile — severe dyskinesias, mild pre-existing anxiety, and mildly reduced neuropsychological scores — specifically favors GPi as the DBS target. GPi DBS has two key advantages for this patient. First, it carries a lower risk of the mood and cognitive adverse effects that are occasionally seen with STN stimulation, including depression, anxiety exacerbation, and neuropsychiatric change — findings supported by the VA/NINDS cooperative study, which demonstrated better Mattis Dementia Rating Scale and depressive symptom scores in GPi DBS patients at 24 months. For a patient with pre-existing anxiety and cognitive vulnerability, this reduced neuropsychiatric risk is clinically significant. Second, GPi DBS provides direct antidyskinetic benefit through modulation of GPi output — the final common output nucleus of the basal ganglia — that is independent of levodopa dose reduction. This means his levodopa doses can be maintained or even increased to optimize motor benefit while still achieving dyskinesia control. By contrast, STN DBS achieves its antidyskinetic effect primarily through the levodopa dose reduction it permits (mean ~50% reduction in levodopa equivalent dose), and in a patient with severe dyskinesias this dose reduction is necessary but must be managed carefully.
Option A: Option A is incorrect; the VA/NINDS cooperative study did not find that STN DBS produced superior overall motor UPDRS scores in all patient subgroups — it found no significant difference in overall motor outcomes between the two targets at 24 months. The premise of this option is factually incorrect.
Option B: Option B is incorrect; GPi DBS does not increase levodopa dose requirements. It permits doses to be maintained or increased without worsening dyskinesia, but this is not because GPi stimulation requires higher levodopa — it is because the direct antidyskinetic effect removes the dose ceiling that dyskinesias would otherwise impose.
Option C: Option C is incorrect; STN DBS does not directly suppress direct pathway medium spiny neurons responsible for dyskinesia. The STN is an excitatory glutamatergic nucleus that drives the indirect pathway output to the GPi/SNr; it does not directly modulate the direct pathway D1-expressing MSNs that are sensitized in LID. STN DBS's antidyskinetic effect is indirect, primarily mediated through the levodopa dose reduction it enables.
Option E: Option E is incorrect; the VA/NINDS cooperative study specifically found differences in cognitive and psychiatric outcomes favoring GPi DBS, and patient-specific factors including pre-existing neuropsychiatric vulnerabilities are clinically determinative in target selection — the choice is not interchangeable for this patient.
16. A 66-year-old woman with Parkinson's disease on carbidopa/levodopa 25/100 mg three times daily reports 45–60 minutes of wearing-off before each dose despite feeling well-controlled during the on state. Her neurologist applies the step-by-step wearing-off management algorithm. Which of the following correctly sequences the initial pharmacological interventions in order of priority, and identifies the mechanistic rationale that distinguishes the first step from subsequent ones?
A) First, add entacapone 200 mg with each levodopa dose to extend plasma levodopa half-life through peripheral COMT inhibition; second, shorten the dose interval; third, add rasagiline to reduce central dopamine catabolism; the rationale for starting with COMT inhibition is that it addresses both the pharmacokinetic shortfall and the risk of dyskinesia amplification from dose interval shortening
B) First, switch immediately to extended-release carbidopa/levodopa to eliminate peak-to-trough concentration fluctuations; second, add a dopamine agonist; third, add entacapone; the rationale is that controlled-release formulations address the root pharmacokinetic cause of wearing-off more completely than any oral dosing frequency adjustment
C) First, shorten the dose interval — increasing from three to four or five daily doses while maintaining the current individual dose — because most wearing-off is a timing problem reflecting an inter-dose interval that exceeds the levodopa plasma half-life rather than a dose insufficiency; second, add a COMT inhibitor to extend plasma levodopa half-life if interval shortening is insufficient; third, add a MAO-B inhibitor to reduce central dopamine catabolism as a complementary pharmacodynamic intervention
D) First, increase the individual levodopa dose while maintaining three-times-daily frequency to raise the peak plasma concentration and extend the duration of therapeutic effect per dose; second, add entacapone; third, consider extended-release formulation; the rationale is that sub-therapeutic peak concentration — not dosing frequency — is the primary cause of wearing-off in patients responding well to their current dose
E) First, add a long-acting dopamine agonist to provide continuous receptor stimulation that compensates for levodopa trough periods; second, shorten the dose interval; third, add entacapone; the rationale is that the continuous dopaminergic stimulation hypothesis identifies tonic receptor occupation as the goal, and a long-acting agonist most directly achieves this without amplifying the pulsatile levodopa oscillations responsible for sensitization
ANSWER: C
Rationale:
Option C is correct. The wearing-off management algorithm described in the Park-03 module follows a clear sequence grounded in pharmacological reasoning. The first step — shortening the dose interval by increasing from three to four or five daily doses while keeping the individual dose stable — is prioritized because most wearing-off in patients who are otherwise well-controlled represents a timing problem rather than a dose insufficiency. Levodopa's plasma half-life is approximately 90 minutes, and a three-times-daily schedule creates inter-dose intervals of approximately 4–5 hours during waking hours — far exceeding the duration of the therapeutic plasma concentration. The immediate pharmacological correction is to ensure the next dose arrives before the previous one has fully worn off, by reducing the interval. Critically, this approach corrects the trough without amplifying the peak concentration, thereby avoiding increased dyskinesia risk. If interval shortening is insufficient, the second step is addition of a COMT inhibitor — entacapone 200 mg with each dose, opicapone 50 mg once daily, or tolcapone where hepatotoxicity monitoring is feasible — which reduces peripheral O-methylation of levodopa to 3-OMD, extending the plasma half-life and broadening the therapeutic concentration window per dose through a pharmacokinetic mechanism complementary to dosing frequency. The third step, adding a MAO-B inhibitor such as rasagiline or selegiline, addresses central dopamine catabolism — a pharmacodynamic mechanism that extends the duration of each levodopa dose's central effect without substantially altering plasma pharmacokinetics. These three mechanisms are distinct and complementary.
Option A: Option A is incorrect; the algorithm specifies interval shortening as the first step, not COMT inhibitor addition. COMT inhibition is the second-line intervention when interval adjustment is insufficient, not the starting point.
Option B: Option B is incorrect; immediate switch to extended-release carbidopa/levodopa is not the first step — the evidence for ER formulations reducing wearing-off versus optimized IR dosing is modest, and interval shortening with IR remains the recommended first intervention.
Option D: Option D is incorrect; increasing the individual dose while maintaining three-times-daily frequency amplifies peak concentrations and increases dyskinesia risk without correcting the inter-dose timing problem that is the primary cause of wearing-off in this patient.
Option E: Option E is incorrect; adding a dopamine agonist first is not the initial step in the wearing-off algorithm — it comes later in the sequence when oral optimization with dosing frequency and adjunctive agents has been attempted. Agonists are used as adjuncts to levodopa in refractory wearing-off, not as the first pharmacological intervention.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.